Because nucleoside antivirals (NA) only inhibit viral replication and have no effect on the body’s immune system, they require long-term dosing to maintain antiviral effects, making it difficult to obtain a durable response after discontinuation, and a high proportion of patients who discontinue them even as recommended by guidelines experience relapse. Some studies suggest that quantitative HBsAg levels at the time of drug discontinuation can help predict the risk of relapse after drug discontinuation, and in addition, PEG-IFN therapy may open a new pathway for NA treated patients to achieve durable post-treatment responses and pursue higher therapeutic endpoints.